keyword
MENU ▼
Read by QxMD icon Read
search

Risedronate

keyword
https://www.readbyqxmd.com/read/29752905/paget-s-disease-of-bone-diagnosis-and-treatment-%C3%A2-%C3%A2-%C3%A2-%C3%A2-%C3%A2-%C3%A2
#1
REVIEW
Igor Kravets
Paget's disease of bone is a common bone disorder characterized by disorganized bone remodeling. The most likely etiology is a slow paramyxoviral viral infection in genetically susceptible individuals, however the exact cause is unknown. Enhanced bone resorption due to and increased activity of osteoclasts recruits numerous osteoblasts to resorption sites with large quantities of new bone matrix produced as a result. The accelerated bone resorption and formation are not as closely coupled as in a healthy bone; a disorganized bone tissue is formed...
May 9, 2018: American Journal of Medicine
https://www.readbyqxmd.com/read/29737412/factors-associated-with-inadequate-responses-to-risedronate-in-japanese-patients-with-osteoporosis
#2
Ryo Okazaki, Ryoichi Muraoka, Masayuki Maehara, Daisuke Inoue
Factors associated with an inadequate response (IR) to bisphosphonates have been reported in many countries, but not in Japan, where the approved dose is half the global dose. We analyzed factors associated with IR to risedronate in Japanese patients with osteoporosis. This was a post hoc analysis of 1261 Japanese osteoporosis patients who received risedronate for 1 year in phase III trials. IR was defined as more than one new vertebral fracture (VF) and/or negative change in lumbar spine bone mineral density (BMD) at 1 year...
May 8, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29724093/the-effect-of-postoperative-use-of-teriparatide-reducing-screw-loosening-in-osteoporotic-patients
#3
Jae Wook Kim, Seung Won Park, Young Baeg Kim, Myeong Jin Ko
Objective: The loosening of pedicle screws (PS) is one of the frequent problems of spinal surgery in the patients with osteoporosis. Previous studies had revealed that intermittent injection of teriparatide could reduce PS loosening by improving bone mass and quality when their patients took parathyroid hormone for a considerable duration before surgery. However, although the teriparatide is usually used after spine surgery in most clinical situations, there was no report on the efficacy of teriparatide treatment started after spine surgery...
May 4, 2018: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/29713181/minodronate-for-the-treatment-of-osteoporosis
#4
REVIEW
Tsuyoshi Ohishi, Yukihiro Matsuyama
Minodronate is a third-generation bisphosphonate that was developed and approved for clinical use in osteoporosis therapy in Japan. The mechanism of action for suppressing bone resorption is the inhibition of farnesyl pyrophosphate synthase, a key enzyme in the mevalonic acid metabolic pathway of osteoclasts, to induce apoptosis of the cells. Minodronate is the strongest inhibitor of bone resorption among the currently available oral bisphosphonates. Large randomized, placebo-controlled, double-blind clinical trials have revealed an increase in bone mineral density of both the lumbar spine and femoral neck over 3 years of daily minodronate therapy and risk reduction in vertebral fractures over 2 years of therapy...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29702983/effect-of-risedronate-on-femoral-periprosthetic-bone-loss-following-total-hip-replacement-a-systematic-review-and-meta-analysis
#5
Liang Ren, Weidong Wang
BACKGROUND: Recent study has reported that risedronate was effective in reducing periprosthesis bone loss after total hip arthroplasty (THA). The meta-analysis was performed to compare the clinical outcomes of THA with oral risedronate versus placebo. METHODS: Electronic databases: PubMed (1950-March 2018), EMBASE (1974-March 2018), the Cochrane Central Register of Controlled Trials, Web of Science (1950-March 2018) were systematically searched. Two authors independently graded the methodological quality of each eligible study using the Cochrane Collaboration tool and extracted relevant data...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29665839/the-efficiency-of-risedronate-in-reducing-bone-resorption-after-total-hip-arthroplasty-a-meta-analysis-of-randomized-control-trials-at-a-minimum-of-6-months-follow-up
#6
Liqing Yang
BACKGROUND: Recently risedronate is suggested to be effective for the prevention and treatment of for osteoporosis in total hip arthroplasty. This meta-analysis aimes to evaluate the efficacy of risedronate in reducing femoral periprosthetic bone mineral density loss in patients undergoing primary total hip arthroplasty. METHODS: A systematic search was performed in Medline (1966-31 October 2017), PubMed (1966-31 October 2017), Embase (1980-31 October 2017), ScienceDirect (1985-31 October 2017) and the Cochrane Library...
April 17, 2018: Journal of Orthopaedic Surgery and Research
https://www.readbyqxmd.com/read/29616561/denosumab-a-unique-perspective-on-adherence-and-cost-effectiveness-compared-with-oral-bisphosphonates-in-osteoporosis-patients
#7
Paige Morizio, Jena I Burkhart, Sachiko Ozawa
OBJECTIVE: To assess the cost-effectiveness as well as adherence and patient preference for denosumab compared with oral bisphosphonates for the treatment of osteoporosis. DATA SOURCES: Two comprehensive PubMed literature searches (from data inception to December 2017) were performed. The first search included the terms osteoporosis, denosumab, bisphosphonate, and adherence or persistence or compliance or preference. The search terms osteoporosis, denosumab, cost, and effectiveness were used in the second literature search...
April 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29607978/the-efficacy-of-minodronate-in-the-treatment-of-glucocorticoid-induced-osteoporosis
#8
Eriko Hasegawa, Satoshi Ito, Chinatsu Takai, Daisuke Kobayashi, Yumi Nomura, Hiroshi Otani, Asami Abe, Hajime Ishikawa, Akira Murasawa, Ichiei Narita, Kiyoshi Nakazono
Objective To investigate the efficacy of minodronate in the treatment of glucocorticoid-induced osteoporosis (GIO). Methods The study population included patients in whom the administration of minodronate (50 mg, once every 4 weeks) had been newly started for the treatment of GIO in Niigata Rheumatic Center from 2012 to 2015. Patients who were bisphosphonate-naïve and those who switched from other bisphosphonates were classified into the naïve and switch groups, respectively. The changes in the bone mineral density (BMD) and bone metabolic markers after one year of minodronate treatment were retrospectively evaluated...
March 30, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29604369/star-shaped-poly-oligoethylene-glycol-copolymer-based-gels-thermo-responsive-behaviour-and-bioapplicability-for-risedronate-intranasal-delivery
#9
Mahmoud E Soliman, Enas Elmowafy, Luca Casettari, Cameron Alexander
The aim of this work was to obtain an intranasal delivery system with improved mechanical and mucoadhesive properties that could provide prolonged retention time for the delivery of risedronate (RS). For this, novel in situ forming gels comprising thermo-responsive star-shaped polymers, utilizing either polyethylene glycol methyl ether (PEGMA-ME 188, Mn 188) or polyethylene glycol ethyl ether (PEGMA-EE 246, Mn 246), with polyethylene glycol methyl ether (PEGMA-ME 475, Mn 475), were synthesized and characterized...
March 28, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29603071/serum-homocysteine-levels-are-affected-by-renal-function-during-a-3-year-period-of-minodronate-therapy-in-female-osteoporotic-patients
#10
Tsuyoshi Ohishi, Tomotada Fujita, Daisuke Suzuki, Tatsuya Nishida, Mitsuru Asukai, Yukihiro Matsuyama
Serum homocysteine is a possible marker to indicate bone quality. However, it is not clear whether changes are seen in serum homocysteine levels with long-term bisphosphonate therapy. We aimed to investigate the factors affecting serum homocysteine levels during a 3-year period of monthly minodronate therapy in osteoporotic women, and to examine if the serum homocysteine levels could reflect some aspects of bone metabolism. The study included 43 patients (age 72.3 ± 7.0 years) undergoing treatment for osteoporosis for the first time (New group) and 35 patients (age 74...
March 30, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29574518/effects-of-once-monthly-minodronate-versus-risedronate-in-osteoporosis-patients-with-rheumatoid-arthritis-a-12-month-randomized-head-to-head-comparison
#11
K Kumagai, K Harigane, Y Kusayama, T Tezuka, H Choe, Y Inaba, T Saito
A head-to-head comparison of once-monthly oral bisphosphonates minodronate (MIN) and risedronate (RIS) in patients with rheumatoid arthritis (RA) demonstrated that MIN has the same effect as RIS on increase in bone mineral density (BMD) and a stronger effect on inhibition of bone resorption than RIS, suggesting that MIN is a promising treatment option for osteoporosis patients with RA. INTRODUCTION: To evaluate the effect of once-monthly oral MIN in patients with RA, a prospective, randomized, open-label, head-to-head comparison with once-monthly oral RIS was conducted...
March 24, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29564150/fabrication-of-a-microfluidic-device-for-studying-the-in-situ-drug-loading-release-behavior-of-graphene-oxide-encapsulated-hydrogel-beads
#12
Sarath Chandra Veerla, Da Reum Kim, Sung Yun Yang
Background: Controlled drug delivery system is highly important for not only prolonged the efficacy of drug but also cellular development for tissue engineering. A number of biopolymer composites and nanostructured carriers behave been used for the controlled drug delivery of therapeutics. Recently, in vitro microfluidic devices that mimic the human body have been developed for drug-delivery applications. Methods: A microfluidic channel was fabricated via a two-step process: (i) polydimethyl siloxane (PDMS) and curing agent were poured with a 10:2 mass ratio onto an acrylic mold with two steel pipes, and (ii) calcium alginate beads were synthesized using sodium alginate and calcium chloride solutions...
2018: Biomaterials Research
https://www.readbyqxmd.com/read/29525970/effects-of-discontinuing-oral-bisphosphonate-treatments-for-postmenopausal-osteoporosis-on-bone-turnover-markers-and-bone-density
#13
K E Naylor, M Bradburn, M A Paggiosi, F Gossiel, N F A Peel, E V McCloskey, J S Walsh, R Eastell
The antiresorptive potency varies between different bisphosphonates. We investigated the effect of stopping oral bisphosphonate treatment for postmenopausal osteoporosis (ibandronate, alendronate, risedronate) on BTMs and BMD. After stopping treatment, all three groups showed an increase in BTMs and a decrease in hip BMD; however, none returned to pre-treatment baseline values. INTRODUCTION: Bisphosphonates (BPs) continue to suppress bone turnover markers (BTMs) after treatment has stopped, leading to the suggestion that a pause in treatment could be considered for low-risk patients...
March 10, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29448032/risedronate-reduces-postoperative-bone-resorption-after-cementless-total-hip-arthroplasty-a-systematic-review-and-meta-analysis
#14
Meng Wang, Liang Wang, Ruqing Ye
OBJECTIVE: To examine the effects of risedronate for reducing periprosthetic bone loss after total hip arthroplasty (THA). METHODS: Two reviewers performed an electronic literature search for randomized controlled trial (RCTs) evaluating the risedronate in the management of periprosthetic bone loss after primary THA. The electronic databases include PubMed, Medline, Embase, Web of Science and the Cochrane Library from inception to January 2018. We assessed the risk of bias using the Cochrane risk-of-bias tool...
April 2018: International Journal of Surgery
https://www.readbyqxmd.com/read/29445836/bone-loss-after-romosozumab-denosumab-effects-of-bisphosphonates
#15
Anne M Horne, Borislav Mihov, Ian R Reid
Romosozumab and denosumab are monoclonal antibodies for the treatment of osteoporosis. Both have a rapid offset of effect resulting in loss of bone density (BMD) gained on-treatment and, in some cases, multiple vertebral fractures following treatment cessation. We recently reported disappointing results from transitioning patients from denosumab to intravenous zoledronate at the time the next denosumab injection is due. The present report re-assesses the role of bisphosphonates following the use of denosumab...
February 14, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29411304/efficacy-of-anti-osteoporotic-medications-in-patients-with-type-1-and-2-diabetes-mellitus-a-systematic-review
#16
REVIEW
Panagiotis Anagnostis, Stavroula A Paschou, Nifon N Gkekas, Aikaterini-Maria Artzouchaltzi, Konstantinos Christou, Dimitrios Stogiannou, Andromachi Vryonidou, Michael Potoupnis, Dimitrios G Goulis
PURPOSE: Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have been associated with bone fragility and increased fracture risk. However, little is known regarding the effect of anti-osteoporotic treatment on bone mineral density (BMD) and/or fracture risk in these patients. We aimed to systematically investigate the efficacy of anti-osteoporotic medications in patients with diabetes in comparison with non-diabetic subjects. METHODS: MEDLINE and Scopus databases were searched (up to 31st October 2017)...
February 6, 2018: Endocrine
https://www.readbyqxmd.com/read/29386866/osteoporosis-a-review-of-treatment-options
#17
Kristie N Tu, Janette D Lie, Chew King Victoria Wan, Madison Cameron, Alaina G Austel, Jenny K Nguyen, Kevin Van, Diana Hyun
Approximately 10 million men and women in the U.S. have osteoporosis,1 a metabolic bone disease characterized by low bone density and deterioration of bone architecture that increase the risk of fractures.2 Osteoporosis-related fractures can increase pain, disability, nursing home placement, total health care costs, and mortality.3 The diagnosis of osteoporosis is primarily determined by measuring bone mineral density (BMD) using noninvasive dual-energy x-ray absorptiometry. Osteoporosis medications include bisphosphonates, receptor activator of nuclear factor kappa-B ligand inhibitors, estrogen agonists/antagonists, parathyroid hormone analogues, and calcitonin...
February 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/29337454/-osteoporosis
#18
Brigitte Uebelhart, Serge Ferrari
The risk for a second fracture within two years after a first one is high. Ten years denosumab treatment show favorable results with a risk of early vertebral fractures in patients with prevalent vertebral fractures when treatment is stopped. Teriparatide is more effective than risedronate to prevent vertebral and clinical fractures in high risk patients. Romosozumab acts as an anabolic agent in osteoporosis. Atypical femoral fractures associated with bisphosphonate treatment could be more frequent in patients with particular anatomical features...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29329484/effects-of-teriparatide-compared-with-risedronate-on-the-risk-of-fractures-in-subgroups-of-postmenopausal-women-with-severe-osteoporosis-the-vero-trial
#19
Piet Geusens, Fernando Marin, David L Kendler, Luis A Russo, Cristiano Af Zerbini, Salvatore Minisola, Jean Jacques Body, Eric Lespessailles, Susan L Greenspan, Alicia Bagur, Jan J Stepan, Péter Lakatos, Enrique Casado, Rüdiger Moericke, Pedro López-Romero, Astrid Fahrleitner-Pammer
The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), and bone mineral density (BMD) T-score ≤-1.5. Patients were treated with either s.c. daily teriparatide 20 μg or oral weekly risedronate 35 mg. As previously reported, the risk of new VFx and clinical fractures (a composite of clinical VFx and nonvertebral fragility fractures [NVFFx]) was statistically significantly reduced with teriparatide compared with risedronate...
January 12, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29236162/bisphosphonates-prevent-age-related-weight-loss-in-japanese-postmenopausal-women
#20
Tomohiko Urano, Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka, Fumihiko Urano, Kazuhiro Uenishi, Satoshi Inoue
Decline of body weight with aging is a major risk factor for frailty, osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. Recently, we have shown that 5-year treatment with raloxifene prevented age-related weight loss, suggesting some other drugs for osteoporosis may also prevent a decrease in body weight with aging. The present study aimed to identify the relationship between bisphosphonate treatment and body composition markers. We measured bone mineral density (BMD), body composition, and bone remodeling markers in 551 Japanese postmenopausal women with bisphosphonate treatment, which included risedronate or alendronate treatment (BP-treatment group; N = 193) and without treatment by any osteoporosis drug (no-treatment group; N = 358) for 4-7 years (mean observation periods; 5...
December 13, 2017: Journal of Bone and Mineral Metabolism
keyword
keyword
27345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"